Est. 2001·3,000+ placements · six offices · four regions
Product Launchcurated sourcedetected 2026-09-29 · confidence 95%

Last updated

DBV Technologies: Product Launch

DBV Technologies submitted a Biologics License Application to the U.S. FDA for VIASKIN® Peanut Patch for children aged 4-7 years, advancing its immunotherapy product through regulatory pathway.

Source: GlobeNewswire

Who
DBV Technologies · Biotech & Pharma · USA
What happened
DBV Technologies submitted a Biologics License Application to the U.S. FDA for VIASKIN® Peanut Patch for children aged 4-7 years, advancing its immunotherapy product through regulatory pathway.
When
2026-09-29
So what
DBV Technologies's launch shifts talent demand before revenue catches up.

The leadership read

DBV Technologies's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether DBV Technologies backs it with senior go-to-market hires across Americas. That separates a platform move from a one-off.

Market context: Backdrop: a 95.4 (Cool) Talent Market Index (down 5.3 on the month) with Americas activity easing (-16.2pts).

DBV Technologies: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies.

MitchelLake in this thematic

More signals across Biotech & Pharma

Product Launch · Americas

ABEC →

ABEC announced the commercial launch of the ATB-2100 Advanced Therapy Bioreactor, a single-use cell expansion platform aimed at advanced therapy (cell and gene therapy) manufacturing.

Product Launch · Americas

Thermo Fisher Scientific →

Thermo Fisher Scientific launched Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin-free basal and feed media in liquid and dry powder formats for CHO-K1 cell line support in biologics and biosimilars production.

Product Launch · Americas

Teva Pharmaceutical Industries Ltd. →

Teva received U.S. FDA approval for DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab), for treatment of bone complications in advanced cancer patients, giant cell tumor of bone, and hypercalcemia of malignancy.

Product Launch · Americas

ACROBiosystems →

ACROBiosystems launched ACRO AIx and CHO-Direct platforms, plus GlobalLifeShip cross-border supply chain solution, positioned for AI-driven drug discovery (AIDD) workflows.

Product Launch · Americas

Bristol Myers Squibb →

FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.

Product Launch · Americas

Amgen →

Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.

Where this lands in our work

Weekly briefing

Track companies like DBV Technologies — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record